The effects of depressed mood on smoking cessation: Mediation by postcessation self-efficacy.

Cinciripini, Paul M.; Wetter, David W.; Fouladi, Rachel T.; Blalock, Janice A.; Carter, Brian L.; Cinciripini, Lynn G.; Baile, Walter F.

doi:10.1037/0022-006x.71.2.292

Cited by 161 publications

(133 citation statements)

References 59 publications

(68 reference statements)

Supporting

Mentioning

113

Contrasting

Unclassified

Order By: Relevance

“…A recent review and meta-analysis found that past major depression was associated with a statistically significant, but modest, decrease in both short-and long-term abstinence rates [13]. Having experienced depression and pre-cessation depressed mood have also been found to be associated with increased relapse [14,15]. In older smokers (not all of whom were attempting to quit), level of depression predicted continued smoking [11], and there is evidence across all ages that the negative effect of depression on cessation is stronger for women [16,17].…”

Section: Introductionmentioning

confidence: 99%

Depression and Smoking Cessation: Evidence from a Smoking Cessation Clinic with 1-Year Follow-Up

et al. 2016

View full text Add to dashboard Cite

Background Smoking is more prevalent among people with depression. Depression may make cessation more difficult and cessation may affect depression symptoms. Purpose The aims of this study were to assess the associations between (1) baseline depression and 1-year smoking abstinence and (2) abstinence and change in depression. Methods Observational study using data collected routinely in a smoking cessation clinic in the Czech Republic from 2008 to 2014. Aim 1: N = 3775 patients; 14.3% reported mild and 15.4% moderate/severe baseline depression levels measured using Beck's Depression Inventory (BDI-II). Logistic regressions assessed if depression level predicted 1-year biochemically verified abstinence while adjusting for patient and treatment characteristics. Aim 2: N = 835 patients abstinent at 1 year; change in depression was analysed using Chi-square statistics, t test and mixed method analyses of variance. Results Rate of abstinence was lower for patients with mild (32.5%, OR = 0.68; 95% CI: 0.54 to 0.87, p = 0.002) and moderate/severe depression (25.8%; OR = 0.57, 95% CI: 0.45 to 0.74, p < 0.001) compared with patients without depression (40.5%).Across abstinent patients, the majority with baseline depression reported lower depression levels at follow-up. Overall mean (SD) BDI-II scores improved from 9.2 (8.6) to 5.3 (6.1); t(834) = 14.6, p < 0.001. There were significant main effects of time (F(1832) = 880.8, p < 0.001, partial η 2 = 0.51) and baseline depression level (F(2832) = 666.4, p < 0.001, partial η 2 = 0.62) on follow-up depression and a significant depression * time interaction (F(2832) = 296.5, p < 0.001, partial η 2 = 0.42). Conclusions In this effective smoking cessation clinic, depression at the start of treatment predicted reduced smoking abstinence 1 year later. Patients abstinent from smoking experienced considerable improvement in depression.

show abstract

Section: Introductionmentioning

confidence: 99%

Depression and Smoking Cessation: Evidence from a Smoking Cessation Clinic with 1-Year Follow-Up

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Although conflicting evidence exists regarding the relationship between having a history of MDD and smoking cessation outcomes (Covey, 2004;Hall, 2004;Hitsman, Borrelli, McChargue, Spring, & Niaura, 2003), depressive symptoms ) and negative moods (Cinciripini et al, 2003;Ginsberg, Hall, Reus, & Muñoz, 1995;Killen et al, 1996;Kinnunen, Doherty, Militello, & Garvey, 1996) have been consistently associated with poorer smoking outcomes.…”

Section: Introductionmentioning

confidence: 99%

Bupropion and cognitive-behavioral treatment for depression in smoking cessation

Brown

Niaura

Lloyd-Richardson

et al. 2007

CNTR

View full text Add to dashboard Cite

This study is a randomized, double-blind, placebo-controlled clinical trial examining the effects of an intensive cognitive-behavioral mood management treatment (CBTD) and of bupropion, both singularly and in combination, on smoking cessation in adult smokers. As an extension of our previous work, we planned to examine the synergistic effects of CBTD and bupropion on smoking cessation outcomes in general and among smokers with depression vulnerability factors. Participants were 524 smokers (47.5% female, M age =44.27 years) who were randomized to one of four 12-week treatments: (a) standard, cognitive-behavioral smoking cessation treatment (ST) plus bupropion (BUP), (b) ST plus placebo (PLAC), (c) standard cessation treatment combined with cognitivebehavioral treatment for depression (CBTD) plus BUP, and (d) CBTD plus PLAC. Follow-up assessments were conducted 2, 6, and 12 months after treatment, and self-reported abstinence was verified biochemically. Consistent with previous studies, bupropion, in comparison with placebo, resulted in better smoking outcomes in both intensive group treatments. Adding CBTD to standard intensive group treatment did not result in improved smoking cessation outcomes. In addition, neither CBTD nor bupropion, either alone or in combination, was differentially effective for smokers with single-past-episode major depressive disorder (MDD), recurrent MDD, or elevated depressive symptoms. However, findings with regard to recurrent MDD and elevated depressive symptoms should be interpreted with caution given the low rate of recurrent MDD and the low level of depressive symptoms in our sample. An a priori test of treatment effects in smokers with these depression vulnerability factors is warranted in future clinical trials.

show abstract

“…[3][4][5] Smokers with depression are more likely to relapse from a quit attempt, have higher nicotine dependence, suffer negative mood symptoms from withdrawal, and suffer greater smoking-related morbidity and mortality than the general population of smokers. [6][7][8][9][10][11][12] For the general population, effective smoking cessation interventions include nicotine replacement therapy (NRT), 13 antidepressants bupropion and nortriptyline, 14 nicotine receptor partial agonists varenicline, 15 and smoking cessation counseling. [16][17][18] Pharmacological and behavioral strategies increase the likelihood of successful quits attempt by 1.5 to 2 times compared to placebo or usual care.…”

mentioning

confidence: 99%

“…19 Depression status may influence patients' ability to engage in smoking cessation. 6,7,9 Some evidence supports that smokers with current depression are less likely to succeed with smoking cessation compared to history positive patients.…”

mentioning

confidence: 99%

Smoking Cessation Interventions for Patients with Depression: A Systematic Review and Meta-analysis

et al. 2011

View full text Add to dashboard Cite

OBJECTIVES:We conducted a systematic literature review of smoking cessation interventions for patients with histories of depressive disorders or current significant depressive symptoms. We examined the comparative effectiveness of smoking cessation strategies on abstinence rates, differential effects of cessation strategies by depression status (i.e., history positive vs. current depression), and differential effects by gender. DATA SOURCES: Peer-reviewed literature in MEDLINE, Embase, PsycINFO, and Cochrane Library. STUDY ELIGIBILITY CRITERIA, PARTICIPANTS, AND INTERVENTIONS: Randomized controlled trials or secondary analysis of RCT data comparing two or more smoking cessation interventions or intervention to control, and reporting cessation outcomes in adults with depression. STUDY APPRAISAL AND SYNTHESIS METHODS: Two trained researchers screened articles for inclusion. When possible, we estimated pooled risk ratios with 95% confidence intervals by using a random effects model with the Mantel-Haenszel method. We synthesized other studies qualitatively. We classified each intervention as antidepressants, nicotine replacement therapy (NRT), brief smoking cessation counseling, smoking cessation behavioral counseling, or behavioral mood management. RESULTS: We identified 16 unique RCTs, of which, only three trials recruited participants with current depression. Meta-analysis demonstrated a small, positive effect of adding behavioral mood management (RR = 1.41, 95% CI 1.01-1.96). All included antidepressant trials showed small, positive effects, but risk ratio summary was not significant (RR = 1.31, 95% CI 0.73-2.34). Three NRT trials demonstrated small, positive effects on smoking cessation rates. We found insufficient evidence to examine gender and depression status moderator effects. LIMITATIONS: Few RCTs exist that test smoking cessation interventions among adults with depression. To make meaningful comparisons, we created broad intervention categories that contained heterogeneity. CONCLUSIONS AND IMPLICATIONS OF KEY FINDINGS:Few trials enrolled smokers with current depression. Most of data identified were from subgroup analyses of patients history-positive for depression. However, several promising interventions exist. Healthcare providers should consider encouraging their patients with significant depressive symptoms or depression histories to seek smoking cessation services that include NRT and behavioral mood management.

show abstract

The effects of depressed mood on smoking cessation: Mediation by postcessation self-efficacy.

Cited by 161 publications

References 59 publications

Depression and Smoking Cessation: Evidence from a Smoking Cessation Clinic with 1-Year Follow-Up

Depression and Smoking Cessation: Evidence from a Smoking Cessation Clinic with 1-Year Follow-Up

Bupropion and cognitive-behavioral treatment for depression in smoking cessation

Smoking Cessation Interventions for Patients with Depression: A Systematic Review and Meta-analysis

Contact Info

Product

Resources

About